CIK 0001607678 · Large accelerated filer
Viking Therapeutics, Inc.
Sign in to watch- Ticker
- VKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 461073877
- Phone
- 858-704-4660
- Business address
- 9920 PACIFIC HEIGHTS BLVD, SUITE 500, SAN DIEGO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-01-03 | Webster Stephen W Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2017-01-03 | MACARTNEY LAWSON Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2016-11-15 | FOEHR MATTHEW W Director | Purchase | +13,000 | $1.21 | $16K | 39,250 |
| 2016-05-04 | Hanley Rochelle Chief Medical Officer | Shares withheld for taxes | −10,595 | $1.31 | $14K | 160,836 |
| 2016-04-13 | LIGAND PHARMACEUTICALS INC 10% owner | Grant or award | +560,000 | 5,340,964 | ||
| 2016-04-13 | LIGAND PHARMACEUTICALS INC 10% owner | Conversion | +960,000 | $1.25 | $1.2M | 6,300,964 |
| 2016-04-13 | LIGAND PHARMACEUTICALS INC 10% owner | Grant or award · Warrant (right to buy) | +560,000 | 560,000 | ||
| 2016-04-13 | LIGAND PHARMACEUTICALS INC 10% owner | Conversion · Convertible Note (convertible into Common Stock) | −600,000 | $1.25 | $750K | 2,105,139 |
| 2016-04-13 | LIGAND PHARMACEUTICALS INC 10% owner | Conversion · Warrant (right to buy) | +960,000 | 1,520,000 | ||
| 2016-04-13 | LIGAND PHARMACEUTICALS INC 10% owner | Other disposition · Convertible Note (convertible into Common Stock) | −150,000 | $150,000.00 | $22.5B | 1,955,139 |
| 2016-04-13 | FOEHR MATTHEW W Director | Purchase | +20,000 | $1.24 | $25K | 26,250 |
| 2016-04-13 | FOEHR MATTHEW W Director | Purchase · Warrants (Right to Buy) | +20,000 | $0.01 | $200 | 20,000 |
| 2016-03-14 | MORNEAU MICHAEL Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +19,934 | 19,934 | ||
| 2016-03-14 | Lian Brian President & CEO | Grant or award · Stock Option (Right to Buy) | +54,336 | 54,336 | ||
| 2016-03-04 | Hanley Rochelle Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +35,250 | 35,250 | ||
| 2016-03-04 | MORNEAU MICHAEL Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2016-03-04 | Lian Brian President & CEO | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2016-01-04 | Webster Stephen W Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2016-01-04 | SINGLETON J MATTHEW Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2016-01-04 | FOEHR MATTHEW W Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 |
Page 25 of 27 · 528 trades